Accession Therapeutics Limited
Ranjeet B. has extensive work experience in quality assurance and strategy roles. Currently, they are the Head of Quality & Strategy at Accession Therapeutics Limited. Prior to that, they served as the Head of QA at the same company. Before joining Accession Therapeutics Limited, Ranjeet worked as a Director QA at Summit Therapeutics. Ranjeet also held positions at Immunocore as an Interim Head of QA and QA Manager - Clinical. In addition, Ranjeet has experience working in the NHS, where they served as a Quality Programme / JACIE Lead and MDS Bio Data Quality Manager & Stem Cell Quality Manager. Ranjeet started their career at Patheon, where they worked as a Manufacturing Quality Assurance Officer and later as a Manufacturing Support Scientist on the Process Improvement Team.
Ranjeet B. has a Diploma in Management from the University of Leicester. Additionally, they obtained an MSc in Applied Microbiology and a BSc (Hons) in Microbiology & Biochemistry from the University of Westminster. Furthermore, they have completed the GDP Responsible Person Cogent 'Gold Standard' Training from Cogent Skills in July 2020 and the CQI and IRCA Certified ISO 9001:2015 Lead Auditor Training Course (17955) from the British Standards Institution in May 2018.
This person is not in any offices
Accession Therapeutics Limited
Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells.As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour.Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.